newsXospataTM (gilteritinib) has been approved as a monotherapy for patients…
28 October 2019 | By Rachael Harper (European Pharmaceutical Review)
XospataTM (gilteritinib) has been approved as a monotherapy for patients with relapsed or refractory acute myeloid leukaemia with a FLT3 mutation.